Reclutando

Ketamina vs Dexmedetomidina como adyuvante a la Bupivacaína en bloqueo del cuero cabelludo para la hemodinámica y el control del dolor en cirugías de tumores cerebrales

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Objetivo del estudio

Este estudio compara la efectividad en el alivio del dolor de la dexmedetomidina frente a la ketamina, cuando se utilizan junto con bupivacaina en bloqueos del cuero cabelludo, para individuos que se someten a cirugías de tumores cerebrales, midiendo la cantidad total de fentanilo consumida durante la operación.

Qué se está evaluando

Scalp Block with Bupivacaine

+ Scalp Block with Bupivacaine

Medicamento
Quiénes están siendo reclutados

Manifestaciones Neurológicas+1

+ Dolor

+ Signos y Síntomas

De 20 a 60 años
+4 Criterios de eligibilidad
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Tratamiento

Intervencional
Inicio del estudio: enero de 2026
Ver detalles del protocolo

Resumen

Patrocinador PrincipalCairo University
Contacto del EstudioNagy MalakMás contactos
Última actualización: 13 de julio de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 1 de enero de 2026

Fecha en la que se inscribió al primer participante.

The study was designed as a prospective, double-blind, randomized controlled clinical trial to evaluate efficacy of Ketamine versus Dexmedetomidine as an adjuvant to Bupivacaine in Scalp Block in Adults undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamic and Pain Control. The study was carried out in neurosurgery operating rooms at Cairo University Hospital, Faculty of Medicine, Cairo University. The study was approved by the Ethics Committee of Faculty of Medicine, Cairo University, MS-483-2025 Egypt. The trial was preregistered on clinicaltrials.gov, NCT06168903.Written informed consent was obtained from all patients. The Consolidated Standards of Reporting Trials (CONSORT) guidelines were adhered Informed written consent was obtained from each patient. There are adequate provisions to maintain participants' privacy and confidentiality of the data. Randomization will be performed using computer-generated numbers. Allocation concealment will be maintained using serially numbered, opaque, and sealed envelopes. Investigators will remain blind to the sequence, with group assignments contained in envelopes marked only with case numbers. Before each case, a study nurse or assistant will open the corresponding numbered envelope to reveal the patient's group assignment. * Dexmedetomidine (D):): Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 1 µg/kg of dexmedetomidine, with the remainder filled with saline. * Ketamine (K): Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline. The syringes will be prepared by an anesthesia technician and handed blindly to the anesthetist to administer the block. Study Protocol: Patients visited the pre-anesthesia room before the procedure. All patients received explanation of Numerical Rating Scale (NRS) for pain assessment, which ranges from 0 (no pain) to 10 (most severe pain) \[17\]. Standard monitoring was applied, including electrocardiography (ECG), non-invasive, invasive blood pressure, and Oxygen Saturation (SaO₂), and baseline vital signs were recorded, including heart rate, systolic and diastolic blood pressure, mean arterial pressure, and oxygen saturation. Anesthesia was induced with intravenous propofol 2 mg/kg, fentanyl 2 µg/kg, and atracurium 0.5 mg/kg, with mask ventilation for 3 minutes followed by tracheal intubation. Intraoperative signs of inadequate analgesia, such as tachycardia or hypertension exceeding 20% of baseline, were managed with additional 50 µg doses of fentanyl, and total fentanyl consumption was recorded. Anesthesia was maintained using intermittent positive pressure ventilation with isoflurane 0.8-1.2 MAC in an oxygen/air mixture, and atracurium infusion 0.5 mg/kg, while end-tidal CO₂ was monitored. After induction, bilateral scalp blocks were performed using a 23G needle, with local anesthetic infiltrated around supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, lesser occipital, greater occipital, and great auricular nerves, 2-3 mL per nerve. Scalp Block Techniques Supraorbital Nerve Block Patient was seated with the head slightly forward and eyes closed. The supraorbital notch was palpated, and a needle was inserted approximately 1 cm above the notch. 2 ml of local anesthetic were injected at this site. Supratrochlear Nerve Block With the patient in the same position, the injection site was located one finger's breadth medial to the supraorbital nerve. The needle was redirected medially, and 3 mL of local anesthetic was administered. Zygomaticotemporal Nerve Block The patient's head was turned so that the target side was facing upward. Landmarks included the orbital rim and zygomatic arch. A dual injection technique was used, with 1 mL injected deeply and 2 mL subcutaneously. Auriculotemporal Nerve Block The injection site was 1-1.5 cm anterior to the ear, above the tragus, taking care to avoid superficial temporal artery. 3ml of local anesthetic were injected subcutaneously. Greater Occipital Nerve Block With the head turned or the patient seated, the occipital artery was palpated, approximately 3-4 cm lateral to the external occipital protuberance. The needle was inserted perpendicular to the skin medial to the artery, and 3 mL of local anesthetic was injected subcutaneously. Lesser Occipital Nerve Block Injection site was located about 2.5 cm lateral to the greater occipital nerve block site. 3 ml of local anesthetic were administered subcutaneously. Great Auricular Nerve Block (Postauricular Branches) The injection site was 1.5 cm posterior to the ear at the level of the tragus. The needle was inserted perpendicular to the bone, withdrawn slightly, and 3 mL of local anesthetic was injected subcutaneously \[5\]. Hemodynamic Monitoring HR and BP were recorded baseline before induction, 1 and 5 minutes after induction, at intubation, 5 minutes after the scalp block, 5 minutes after pin insertion, 5minutes after skin incision, at 15min, 20min, 25min, 30min,35min, 40min,60min, 95min, 3hour, 4hour and after extubating as well as in post-anesthesia care unit (PACU) and upon arrival in surgical ICU. Deviations from baseline were managed according to protocol: * Bradycardia (<20% below baseline) was treated with atropine 0.04 mg/kg * Hypotension (<20% below baseline) with ephedrine 5 mg IV * Hypertension or tachycardia (>20% above baseline) with fentanyl 50 µg IV. At the end of surgery, residual neuromuscular blockade was reversed using atropine 0.01 mg/kg and neostigmine 0.05 mg/kg. Extubating was performed when the patient met standard criteria, including a Glasgow Coma Scale >8, adequate cough and gag reflex, sufficient motor strength, a train-of-four (TOF) ratio >0.9, ability to hold head tilt or hand grip for 5 seconds, adequate tidal volume and oxygenation and hemodynamic stability. In PACU, standard monitoring was continued, pain was assessed using NRS. Patients were discharged when modified Aldrete Score exceeded 9 \[18\]. Paracetamol and ketorolac were given as rescue analgesia when NRS score was more than 4. The time from extubating to the first analgesic request was recorded, and total postoperative analgesic consumption was documented. Any hemodynamic instability, including hypertension, tachycardia, bradycardia, or hypotension, as well as nausea, vomiting, and other complications, were recorded. Hemodynamic monitoring (MAP in mmHg) was Pain assessment using NRS (0-10) was conducted upon PACU arrival, 2, 4, 6, 8, 12and 24 hours postop

Patrocinador PrincipalCairo University
Contacto del EstudioNagy MalakMás contactos
Última actualización: 13 de julio de 2026
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 90 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Tratamiento

Estos estudios prueban nuevas formas de tratar una enfermedad, condición o problema de salud. El objetivo es determinar si un nuevo medicamento, terapia o enfoque funciona mejor o tiene menos efectos secundarios que las opciones existentes.



Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

De 20 a 60 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Manifestaciones NeurológicasDolorSignos y SíntomasCondiciones Patológicas, Signos y Síntomas

Criterios

2 criterios de inclusión requeridos para participar
Edad de 20 a 60 años, ambos sexos, estado físico de la American Society of Anesthesiologists (ASA) II-III, excisión de tumor supratentorial, posición supina

Tiempo de operación: menos de 6 horas A continuación, se presentan los criterios de elegibilidad del estudio clínico traducidos del inglés al español: 1. Pacientes con diagnóstico confirmado de cáncer de mama. 2. Edad igual o superior a 18 años. 3. Enfermedad medible según los criterios RECIST 1.1. 4. Estado funcional de la OMS (Organización Mundial de la Salud) de 0-1. 5. Adecuada función orgánica, definida por: - Niveles de hemoglobina ≥9 g/dL. - Recuento absoluto de neutrófilos (RAN) ≥1500/mm³. - Recuento de plaquetas ≥100 000/mm³. - Bilirrubina total ≤1,5 veces el límite superior de la normalidad (LSN). - AST (aspartato aminotransferasa) y ALT (alanina aminotransferasa) ≤2,5 veces el LSN (o ≤5 veces el LSN en caso de metástasis hepáticas). - Creatinina ≤1,5 veces el LSN o una depuración de creatinina calculada ≥60 mL/min (según la fórmula de Cockcroft-Gault). 7. Pacientes dispuestos a utilizar métodos anticonceptivos eficaces durante el estudio y hasta 6 meses después de la última dosis del tratamiento en estudio. 8. Consentimiento informado por escrito.

2 criterios de exclusión impiden participar
Se excluyeron pacientes en estado postictal o con convulsiones no controladas/recurrentes, alergia conocida a dexmedetomidina o ketamina, intubación dificultosa (puntuación de Mallampati > III) o múltiples intentos de intubación, duración de la cirugía > 6 horas, disfunción renal (creatinina > 1,2 mg/dL, BUN > 20 mg/dL), bloqueo cardíaco y pacientes con trastornos crónicos de cefalea o aquellos que reciben terapia analgésica crónica (por > 3 meses).

Rechazo del paciente, nivel de conciencia alterado (Escala de Coma de Glasgow [GCS] < 15). Se excluyeron del análisis final a los pacientes que requirieron reintubación durante el período de estudio, aquellos que no fueron extubados inmediatamente después de la cirugía, o aquellos que despertaron con déficits neurológicos que impedían las evaluaciones de dolor, antecedentes de trastornos psicóticos o cirugías previas, mala función cognitiva.

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

2 grupos de intervención están designados en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Experimental
Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 1 µg/kg of dexmedetomidine, with the remainder filled with saline.

Grupo II

Comparador Activo
Patients will receive a scalp block with a 20 ml syringe containing 1 mg/kg of 0.5% bupivacaine and 2 mg/kg of ketamine, with the rest filled with saline. The syringes will be prepared by an anesthesia technician and handed blindly to the anesthetist to administer the block.

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene 2 ubicaciones

Reclutando

Cairo university

Cairo, EgyptAbrir Cairo university en Google Maps
Reclutando

Cairo university Hospitals. kasralainy

Cairo, Egypt
Reclutando
2 Centros de Estudio